Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $832,966.42 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total value of $832,966.42. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at $9,319,952.14. This trade represents a 8.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Chi also recently made the following trade(s):

• On Monday, February 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $43.28, for a total value of $314,169.52.
• On Friday, January 24th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.00, for a total value of $536,424.00.
• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.07, for a total value of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.97, for a total transaction of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total transaction of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24.

Hims & Hers Health Trading Down 1.4 %

Shares of HIMS opened at $41.30 on Friday. The stock’s 50 day moving average is $36.19 and its two-hundred day moving average is $26.46. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The firm has a market capitalization of $9.02 billion, a PE ratio of 93.85 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. Farallon Capital Management LLC lifted its stake in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after acquiring an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $41,104,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after acquiring an additional 1,562,302 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on HIMS. Citigroup boosted their target price on Hims & Hers Health from $25.00 to $27.00 and gave the company a “sell” rating in a report on Tuesday. Piper Sandler boosted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Truist Financial upped their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research report on Wednesday. Finally, Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $35.71.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.